Tempest Therapeutics entered a collaboration agreement with Senlang Biotechnology to advance in vivo CAR-T programs in China, starting with TPST-4003. The parties will run an investigator-initiated trial in about 10 patients with myasthenia gravis or multiple sclerosis, with first dosing expected in Q4 2026. Tempest will pay $1.5–$2.0 million per product in milestone-based fees, capped at $2.0 million unless pre-approved. Tempest receives worldwide, perpetual rights to all generated data, while Senlang holds an exclusive option to negotiate China rights after delivery of agreed IIT data packages.
Agreement details:
- Agreement type: Product Development and Investigator-Initiated Trial Collaboration Agreement
- Counterparty: Senlang Biotechnology
- Signed / Effective: Jul 17 2026 / same
- Duration / Termination: 3 years initial term
- Reason: Advance TPST-4003 China IITs and development
Original SEC Filing:
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.